65 -- Opportunistic Infection Drugs

The Centers for Disease Control and Prevention (CDC) plans to award a sole source, firm fixed-price contract to Central Pharmaceutical Company No. 1 for a one-year supply and distribution of Opportunistic Infection Drugs (OI) within Vietnam. This award is based on the company’s unique qualification stemming from its direct governmental approval by the Vietnamese Government, which restricts the procurement and distribution of OI drugs to only those companies with such approval. This exclusive status ensures compliance with local regulations and facilitates the efficient delivery of these critical drugs. The contract, identified under solicitation number 2005-Q-08075 and associated with the NAICS code 424210, reflects the CDC’s intent to maintain a secure and consistent supply chain for OI drugs in Vietnam. The procurement process involves key points of contact including contract specialists John M Ebanks and Sherry A Smallwood, who manage communication and administrative aspects. This arrangement underscores the CDC’s commitment to collaborating with authorized local partners to meet public health requirements within the regulatory framework of Vietnam.